Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.
Frenel JS, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, De La Motte Rouge T, Saada-Bouzid E, Sabatier R, Lavaud P, Jimenez M, Legrand F, Le Saux O, Charafe E, Gonçalves A.
Frenel JS, et al. Among authors: legrand f.
J Immunother Cancer. 2025 Jan 7;13(1):e010708. doi: 10.1136/jitc-2024-010708.
J Immunother Cancer. 2025.
PMID: 39773562
Free article.
Clinical Trial.